OLMA - CIK 0001750284
The table below shows Olema Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $157.70M | $124.52M | $86.14M | $82.27M | $51.10M | $13.70M |
| SG&A | $21.00M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $17.74M |
| $18.82M |
| $24.71M |
| $20.39M |
| $7.82M |
| Operating income | -$178.70M | -$142.26M | -$104.96M | -$106.99M | -$71.49M | -$21.53M |
| Income tax | $3.00K | $2.00K | $2.00K | $1.00K | - | - |
| Net income | -$162.45M | -$129.47M | -$96.66M | -$104.79M | -$71.10M | -$22.12M |
| EPS (diluted) | -$1.87 | -$2.20 | -$2.14 | -$2.62 | -$1.80 | -$3.42 |